pharmaceutics Article Effective Osteogenic Priming of Mesenchymal Stem Cells through LNA-ASOs-Mediated Sfrp1 Gene Silencing Daniel García-Sánchez 1 , Alberto González-González 1 , Patricia García-García 2 , Ricardo Reyes 3 , María Isabel Pérez-Núñez 4, José A. Riancho 5 , Carmen Évora 2 , José Carlos Rodríguez-Rey 1 and Flor M. Pérez-Campo 1,* 1 Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Cantabria-IDIVAL, 39012 Santander, Spain;
[email protected] (D.G.-S.);
[email protected] (A.G.-G.);
[email protected] (J.C.R.-R.) 2 Department of Chemical Engineering and Pharmaceutical Technology, Institute of Biomedical Technologies (ITB), University of La Laguna, 38206 La Laguna, Spain;
[email protected] (P.G.-G.);
[email protected] (C.É.) 3 Department of Biochemistry, Microbiology, Cellular Biology and Genetics, Institute of Biomedical Technologies (ITB), University of La Laguna, 38200 La Laguna, Spain;
[email protected] 4 Department of Traumatology, Hospital Universitario Marqués de Valdecilla, University of Cantabria, 39008 Santander, Spain;
[email protected] 5 Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla-IDIVAL, University of Cantabria, 39012 Santander, Spain;
[email protected] * Correspondence:
[email protected]; Tel.: +34-942-200-958 Abstract: Mesenchymal stem cell (MSC) transplantation has emerged as a promising approach for Citation: García-Sánchez, D.; bone regeneration. Importantly, the beneficial effects of MSCs can be improved by modulating the González-González, A.; expression levels of specific genes to stimulate MSC osteogenic differentiation. We have previously García-García, P.; Reyes, R.; shown that Smurf1 silencing by using Locked Nucleic Acid-Antisense Oligonucleotides, in combina- Pérez-Núñez, M.I.; Riancho, J.A.; tion with a scaffold that sustainably releases low doses of BMP-2, was able to increase the osteogenic Évora, C.; Rodríguez-Rey, J.C.; Pérez-Campo, F.M.